New member of Elekta's Nomination Committee

Anna Ohlsson-Leijon, representing SEB funds, has been appointed to
Elekta (http://www.elekta.com/)'s Nomination Committee. She replaces
Tove Bångstad who has left her position at SEB. Anna Ohlsson-Leijon is
an independent representative of the Board of Fondbolaget SEB Investment
Management AB since three years.

The Nomination Committee that will prepare matters prior to the Annual
General Meeting 2011 thereby consists of Åsa Nisell, Swedbank Robur
funds, Anna Ohlsson-Leijon, SEB Funds, Ole E. Dahl, Orkla ASA, Laurent
Leksell, representing his private and companies' holdings, and Akbar
Seddigh, Chairman of the Board.

******

For further information, please contact:

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, e-mail:
stina.thorman@elekta.com (stina.thorman@elekta.com)

Elekta AB (publ) discloses the information in this press release
according to the Swedish Securities Markets Act and/or the Swedish
Financial Trading Act. The information was provided for public release
on 31 January 2011 at 15.00 CET.

About Elekta

Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy and radiosurgery, as well as workflow
enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that give confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in more
than 5,000 hospitals globally, and every day more than 100,000 patients
receive diagnosis, treatment or follow-up with the help of a solution
from the Elekta Group.

Elekta employs about 2,500 employees globally. The corporate
headquarters is located in Stockholm, Sweden, and the company is listed
on the Nordic Exchange under the ticker EKTAb.